The Mach7 Technologies Ltd (ASX: M7T) share price is on course to finish the week on a high.
In morning trade the medical imaging data management solutions provider’s shares have rocketed 15% higher to 91.5 cents.
Why is the Mach7 share price rocketing higher?
Investors have been buying the company’s shares following the release of its half year results which revealed stellar profit growth.
For the six months ended December 31, Mach7 reported a 158% increase in revenue over the prior corresponding period to $9.1 million. This was driven by new customer contracts and continued growth in contracted annual recurring revenue (CARR). At the end of the period Mach7’s CARR has increased by 21% to $8.8 million.
Also growing quickly was the company’s earnings. EBITDA came in at $2.3 million and net profit after tax came in at $0.7 million. This was a 176% and 115% increase, respectively, over the prior corresponding period.
This marks the first profit the company has made, which management believes highlights an inflection point for the company. It also notes that it has generated $2.4 million of positive free cash flows from between March 1 and December 31.
At the end of the period the company had $23.3 million in cash and was debt free. As a result, management believes it is well positioned to take advantage of organic and acquisitive growth opportunities.
No guidance was given for the full year, but management appears confident its growth can continue.
Mach7 Managing Director, Mike Lampron, said: “We are pleased with the business and financial outcomes delivered in the first half. Our strategic focus on efficiently scaling the business and serving core customer markets in the US and Asia is working well for our customers, employees and shareholders. We’ll continue to maintain a focus on revenue and profit growth, and generating positive cashflows, building on our success to date.”
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of MACH7 FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- 3 small cap ASX shares to put on your watchlist right now – September 28, 2020 3:00pm
- Why Corp Travel Management (ASX:CTD) and Starpharma (ASX:SPL) shares are in trading halts – September 28, 2020 2:06pm
- Piedmont Lithium (ASX:PLL) share price rockets 83% higher on Tesla deal – September 28, 2020 1:35pm